Pitt Shield

Noninvasive disconnection of targeted neuronal circuitry sparing axons of passage and nonneuronal cells.

Authors: Wang Y, Anzivino MJ, Zhang Y, Bertram EH, Woznak J, Klibanov AL, Dumont E, Wintermark M, Lee KS

Surgery can be highly effective for the treatment of medically intractable, neurological disorders, such as drug-resistant focal epilepsy. However, despite its benefits, surgery remains substantially underutilized due to both surgical concerns and nonsurgical impediments. In this work, the authors characterized a noninvasive, nonablative strategy to focally destroy neurons in the brain parenchyma with the goal of limiting collateral damage to nontarget structures, such as axons of passage. Low-intensity MR-guided focused ultrasound (MRgFUS), together with intravenous microbubbles, was used to open the blood-brain barrier (BBB) in a transient and focal manner in rats. The period of BBB opening was exploited to focally deliver to the brain parenchyma a systemically administered neurotoxin (quinolinic acid) that is well tolerated peripherally and otherwise impermeable to the BBB. Focal neuronal loss was observed in targeted areas of BBB opening, including brain regions that are prime objectives for epilepsy surgery. Notably, other structures in the area of neuronal loss, including axons of passage, glial cells, vasculature, and the ventricular wall, were spared with this procedure. These findings identify a noninvasive, nonablative approach capable of disconnecting neural circuitry while limiting the neuropathological consequences that attend other surgical procedures. Moreover, this strategy allows conformal targeting, which could enhance the precision and expand the treatment envelope for treating irregularly shaped surgical objectives located in difficult-to-reach sites. Finally, if this strategy translates to the clinic, the noninvasive nature and specificity of the procedure could positively influence both physician referrals for and patient confidence in surgery for medically intractable neurological disorders.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To characterize a noninvasive, nonablative MR-guided focused ultrasound approach using transient blood–brain barrier opening and systemic neurotoxin delivery to focally destroy neurons while limiting collateral damage to nontarget structures.
Animal model / Human subject rat, Sprague-Dawley, 5–6 weeks, male
Disease model epilepsy
MRI or image guidance method MR-guided focused ultrasound (MRgFUS)
Targeted brain region(s) Hippocampus
Cargo name and characteristics drug
Route of administration intravenous

Outcomes and Safety

Summary of Outcomes FUS-mediated BBB opening delivered systemic quinolinic acid to produce focal neuronal loss while sparing axons and glia
Duration of biological effect not reported
Safety-related matter Focal neuronal loss achieved with limited collateral damage to vasculature and glial cells

Brain Region

Ultrasound Parameters

Ultrasound instrument RK-100 MR-compatible FUS system
FUS Frequency 1.1 MHz
FUS Intensity not reported
FUS Pressure 0.45 MPa
FUS Mode not reported
Pulse duration 10 ms
Duration of a single FUS session 120 s
Treatment frequency Single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search